XJPX
7741
Market cap48bUSD
Sep 18, Last price
22,605.00JPY
1D
-0.22%
1Q
-17.03%
Jan 2017
360.29%
Name
Hoya Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Tokyo, Japan, in 1941, HOYA Corporation operates as a global med-tech enterprise and a leading provider of advanced technological and medical solutions. Its extensive "life care" division offers a diverse portfolio, ranging from ophthalmic products like eyeglasses and contact lenses to sophisticated medical instruments such as endoscopes, intraocular lenses, laparoscopic surgical tools, and automated endoscope cleaning systems. This segment also supplies various medical-related items, including prosthetic ceramic fillers and metallic implants. Furthermore, HOYA manages Eyecity, a specialized retail chain for contact lenses. Beyond healthcare, the company is a significant contributor to the information technology sector, manufacturing critical components like mask blanks and photomasks for semiconductor and liquid crystal display production, as well as glass disks for hard disk drives. Their imaging product range encompasses optical glasses, lenses, colored glass filters, and laser/UV light resources. Additionally, HOYA develops software solutions, notably ReadSpeaker for speech synthesis, and provides cloud-based services such as Kinnosuke for time and attendance management, and Yonosuke for electronic payslip distribution.
Related entities
Subsidiaries (2)
HOYA LENS BELGIUM
Hoya Medical India Private Limited
Key people
Independent Director · since 2013
Legal address
西新宿6-10-1
東京都 新宿区 160-8347
JP
東京都 新宿区 160-8347
JP
Headquarters
西新宿6-10-1
日土地西新宿ビル
東京都 新宿区 160-8347
JP
日土地西新宿ビル
東京都 新宿区 160-8347
JP
Address
6-10-1, Nishi-Shinjuku
Shinjuku-ku Tokyo 160-8347
JP
Shinjuku-ku Tokyo 160-8347
JP
Other language
HOYA CORPORATION
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||